Compare Crispr Therapeutics AG (CRSP) vs Intel Corp (INTC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Intel Corp — how do they compare? Crispr Therapeutics AG trades at $53.95 (market cap $5.23B), while Intel Corp trades at $100.87 (market cap $492.85B). The key difference: Intel Corp is far larger — about 94.2× Crispr Therapeutics AG's market cap, and Intel Corp pays a 2.24% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | INTC | |
|---|---|---|
Market Cap | $5.23B | $492.85B |
Sector | Health | Technology |
52-Week High | $76.78 | $140.94 |
52-Week Low | $44.34 | $21.81 |
Enterprise Value | $3.65B | $513.66B |
Volume | — | 43,552,012 |
Dividend Yield | — | 2.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $54.02, up 0.95% on the day, with strong technical momentum and bullish moving average signals. The company reported a Q2 2026 loss of $0.94 per share, beating estimates, while revenue growth is driven by CASGEVY sales expansion. Analyst sentiment remains positive with a $82.67 consensus price target representing 53% upside potential.
Despite promising pipeline developments and strong analyst support, CRSP faces significant fundamental challenges including negative profit margins, substantial cash burn, and high valuation multiples. The stock's near-term performance will depend on successful clinical trial outcomes and commercial execution of its gene-editing therapies.
Intel (INTC) trades at $102.74, up 5.35% today, with a bullish technical signal from moving averages but mixed oscillators. Recent earnings beats in Q1 and Q2 2026 highlight improving operational performance, though net income remains negative. The company is raising $20 billion via a stock offering to fund AI and foundry expansion, driving investor focus on growth prospects amid margin challenges.
Outlook: Intel's revenue growth and strategic investments in AI present upside potential, but shareholder dilution from the equity raise and persistent negative margins pose risks. Analyst consensus is mixed with a $116.67 price target, suggesting cautious optimism for the turnaround story.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Intel Corp
Intel Corporation designs, manufactures, and sells computer components and related products. The Company major products include microprocessors, chipsets, embedded processors and microcontrollers, flash memory, graphic, network and communication, systems management software, conferencing, and digital imaging products.
Read more on INTC →
